EAM
PTCT icon

EverPoint Asset Management’s PTC Therapeutics PTCT Stock Holding History

EverPoint Asset Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-387,500
Closed -$10.3M – 511
2015
Q3 		$10.3M Buy
387,500
+262,500
+210% +$11.2M 0.27% 102
2015
Q2 		$6.02M Buy
+125,000
New +$7.29M 0.11% 250

Other funds holding PTCT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

EverPoint Asset Management's PTCT Position: Q4 2016 in Review

EverPoint Asset Management reduced its PTC Therapeutics (PTCT) stake by 87% in Q4 2016, selling an estimated $682K and leaving 10,000 shares worth $109K. The position accounts for ﹤0.01% of the portfolio, ranked #398.

EverPoint Asset Management first reported a position in PTCT in Q3 2014 and has held it in 6 quarters since. The position peaked at $11.9M in Q4 2014. 123 funds tracked by Wall St. Rank hold PTCT as of Q4 2016.

  • EverPoint Asset Management held 10,000 shares of PTC Therapeutics worth $109K as of Q4 2016.
  • EverPoint Asset Management sold 65,000 PTC Therapeutics shares in Q4 2016, an estimated $682K.
  • PTC Therapeutics made up ﹤0.01% of EverPoint Asset Management's portfolio in Q4 2016, its #398 holding.
  • EverPoint Asset Management first reported a position in PTC Therapeutics in Q3 2014 and has held it in 6 quarters since.
  • EverPoint Asset Management's PTC Therapeutics position peaked at $11.9M in Q4 2014.
  • 123 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.